.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,872,701

« Back to Dashboard

Claims for Patent: 6,872,701

Title: Glycopeptide phosphonate derivatives
Abstract:Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
Inventor(s): Leadbetter; Michael R. (San Leandro, CA), Linsell; Martin S. (San Mateo, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Application Number:10/436,341
Patent Claims: 1. A lyophilized composition comprising: (a) a compound of the formula: ##STR9##

or a pharmaceutically acceptable salt thereof; and (b) a cyclodextrin.

2. The composition of claim 1, wherein the cyclodextrin is hydroxypropyl-.beta.-cyclodextrin.

3. The composition of claim 1, wherein the cyclodextrin is sulfobutyl ether .beta.-cyclodextrin.

4. The composition of claim 1, wherein the weight ratio of the cyclodextrin to the compound is from about 1:1 to about 10:1.

5. The composition of claim 1, wherein the pharmaceutically-acceptable salt is a hydrochloride salt.

6. The composition of claim 1, wherein the composition further comprises an excipient selected from the group consisting of mannitol, sucrose, lactose and combinations thereof.

7. The composition of claim 6, wherein the excipient is mannitol.

8. A lyophilized composition comprising: (a) a compound of the formula: ##STR10##

or a hydrochloride salt thereof; (b) hydroxypropl-.beta.-cyclodextrin; and (c) mannitol.

9. A process for preparing a lyophilized composition, wherein the lyophilized composition comprises: (i) a compound of the formula: ##STR11##

or a pharmaceutically-acceptable salt thereof; and (ii) a cyclodextrin; wherein the process comprising the steps of: (a) providing an aqueous solution comprising the compound or pharmaceutically-acceptable salt thereof and the cyclodextrin; and (b) lyophilizing the aqueous solution to provide the lyophilized composition.

10. The process of claim 9, wherein the cyclodextrin is hydroxypropyl-.beta.-cyclodextrin.

11. The process of claim 9, wherein the cyclodextrin is sulfobutyl ether .beta.-cyclodextrin.

12. The process of claim 9, wherein the weight ratio of the cyclodextrin to the compound is from about 1:1 to about 10:1.

13. The process of claim 9, wherein the pharmaceutically-acceptable salt is a hydrochloride salt.

14. The process of claim 9, wherein the composition further comprises an excipient selected from the group consisting of mannitol, sucrose, lactose and combinations thereof.

15. The process of claim 14, wherein the excipient is mannitol.

16. The product prepared by the process of claim 9.

17. A vial containing a lyophilized composition comprising: (a) 250 mg to 1000 mg of a compound of the formula: ##STR12##

or a pharmaceutically-acceptable salt thereof; and (b) 250 mg to 10 g of hydroxypropyl-.beta.-cyclodextrin.

18. The vial of claim 17, wherein the pharmaceutically-acceptable salt is a hydrochloride salt.

19. The vial of claim 17, wherein the lyophilized composition further comprises from 0 to 50 g of an excipient selected from mannitol, sucrose, lactose and combinations thereof.

20. The vial of claim 19, wherein the excipient is mannitol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc